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The cell-surface receptor for advanced glycation end-products (RAGE) has been 
implicated in the development of diabetic vascular complications and Alzheimer's 
disease. RAGE has been considered to be involved in amyloid-1-42 (A1-42) uptake into 
brain. In the present study, we demonstrate that endogenous secretory RAGE (esRAGE), 
a decoy form of RAGE generated by alternative RNA processing, is able to inhibit 
A1-42 influx into mouse brain. Surface plasmon resonance and competitive binding 
assays revealed that human A1-42 interacted with human esRAGE within the 
immunoglobulin V type region. We next examined the uptake and distribution of 
125
I-labeled human A1-42 in various organs and body fluids of newly created mice 
overexpressing human esRAGE as well as RAGE-null and wild-type (WT) mice. The 
transition of the 
125
I-labeled A1-42 from circulation to brain parenchyma peaked at 30 
min after the injection into WT mice, but this was significantly blunted in 
esRAGE-overexpressing and RAGE-null mice. Brain regions where significant 
reduction in 
125
I-labeled A1-42-derived photo-stimulated luminescence were marked in 
ventricles, cerebral cortex, hippocampus, especially CA1 and CA3 regions, putamen, 
and thalamus. The results thus suggest the potential of esRAGE in protection against the 
development of Alzheimer's disease.  
 





     Receptor for advanced glycation end-products (RAGE) is a pattern recognition 
receptor, which binds to not only advanced glycation end-products (AGE) [1], but also 
S100/calgranulins [2], Mac-1 [3], transthyretin [4], high mobility group box-1 
(HMGB-1)/amphoterin [5], lipopolysaccharides (LPS) [6], phosphatidylserine [7], and 
amyloid- (A) [8]. Interactions of these diverse ligands with RAGE contribute to 
various pathologic processes including diabetic complications [9, 10], proinflammatory 
reactions, tumor progression, efferocytosis, and Alzheimer’s disease (AD) [11, 12].  
     The presence of senile plaque formed by extracellular amyloid depositions and 
that of intracellular neurofibrillary tangles composed of hyperphosphorylated tau 
proteins are the major pathological hallmarks of AD [13]. The predominant forms of 
non-fibrillar A that give rise to amyloid plaques are A1-40 and A1-42 fragments [14]. 
While soluble A1-40 is the major form of circulating A and cerebrovascular amyloid, 
the major constituent of amyloid plaques is A1-42. A1-42 rapidly forms oligomers at 
very low concentrations,
 
and thus has been regarded as the major cause of neurotoxicity 





neuronal damage [16, 17].  
Transport of peptides at the blood-brain barrier (BBB) requires a receptor- or 
carrier-mediated transport system [18]. Unrestricted diffusion readily occurs across the 
capillaries in peripheral organs, such as the heart, but not across the BBB [19]. Studies 
using an in vitro model of BBB showed that RAGE mediated the binding of soluble 
A1-40 at the apical side of brain capillary endothelium, and that RAGE was involved in 
A1-40 transcytosis [20]. Low-density lipoprotein receptor-related protein-1 (LRP-1) is 
also known to participate in the receptor-mediated flux of Aacross BBB [21, 22]. 
LRP-1 appears to mediate the efflux of A from the brain to the periphery, whereas 
RAGE is implicated in A influx back into the CNS [22]. Deletion of the RAGE gene 
eliminates the transport of free circulating A into the brain [23]. Giri et al. reported 
that RAGE is also involved in A1-40-mediated migration of monocytes across BBB 
[24].  
     RAGE has multiple isoforms both in human and mouse. Membrane-bound RAGE 
transduces intracellular signaling upon ligand engagement on the cell surface. Soluble 
forms of RAGE act as decoy receptors in the extracellular space [25-29]. Soluble forms 
of RAGE can be generated by the following two mechanisms; one is alternative splicing 
of RAGE transcripts [25], and the other is ectodomain shedding [26-29]. We isolated 
the former variant which is stably present in human blood and named it endogenous 
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secretory RAGE (esRAGE). esRAGE is capable of capturing ligands, thereby 
protecting cells from ligand-induced injury [25]. Immunohistochemical analysis with 
RAGE domain-specific antibodies revealed that expression of esRAGE could be higher 
than that of membrane-bound RAGE in human brain [30]. We also showed lower 
expression of esRAGE in hippocampal CA1 region of AD brain than that of non-AD 
brain [31].  
    These observations have prompted us to determine whether a higher 
concentration of circulating esRAGE could exert a protective effect against AD. In the 
present study, we first confirmed human A-esRAGE interaction, then created 
human esRAGE-overexpressing transgenic (Tg) mice, and compared 
125
I-labeled A1-42 
influx into the brain among wild-type (WT), esRAGE Tg and RAGE-null mice.
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     Human A1-42 peptides for surface plasmon resonance (SPR) and radiolabeling 
were purchased from Sigma-Aldrich Inc. (St. Louis, MO, USA) and Peptide Instutute 
(Osaka, Japan), respectively. FAM-labeled A1-42 peptide for competitive binding assay 
was from AnaSpec Inc. (Fremont, CA, USA) and [
125
I]sodium iodide (NEZ-033A; >600 
GBq/mg) was from PerkinElmer Inc. (Waltham, MA, USA). 
     Human esRAGE-specific antibody used for western blot analysis of sera and for 
ELISA was immunoaffinity-purified rabbit anti-human esRAGE-specific polyclonal 
antibody raised against the unique C-terminal 16-amino-acid peptide (amino acids 
332–347; EGFDKVREAEDSPQHM) [25]. This antibody recognizes human but not 
mouse esRAGE. Pan-RAGE antibody for western blot analysis of brain was goat 
anti-RAGE antibody raised against synthetic peptide that corresponds to amino acids 
42-59 of human RAGE (Millipore). This antibody recognizes both membrane-bound 




      Human esRAGE Tg mice were created as follows. A 1,044-bp fragment of 
human esRAGE cDNA, mouse albumin enhancer/promoter (National Cancer Institute, 
USA) [32], human -globin intron, and SV40 late poly(A) region were used for the 
construction of a transgene (Fig. 2A). The transgene was injected into fertilized BDF1 
ova for production of the Tg mice (Japan SLC, Inc.). Germline transmitted Tg mice 
were then backcrossed into C57BL6/J (>7 generations), and the heterozygous Tg mice 
were used in the current study. Genotyping was carried out by PCR analysis with the 
following primers corresponding to the region of the albumin enhancer/promoter: 
forward, 5’-GCTTGGCTTGAACTCGTT-3’ and reverse, 
5’-GCTACCTTAAAGATCCCG-3’. The transgene-carrying allele yielded a band at 404 
bp on agarose gel electrophoresis. 
     The esRAGE Tg mice, RAGE-null mice developed in our lab [33], and WT 
C57BL/6J mice (Charles River, Yokohama,
 
Kanagawa, Japan) were housed in a 
pathogen-free barrier facility and maintained on normal rodent chow with free access to 
food and water. Male mice at 8~16 weeks of age were used for all experiments. Animals 
were treated in accordance with the Fundamental Guidelines for Proper Conducts of 
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Animal Experiment and Related Activities in Academic Research Institutions under the 
jurisdiction of the Ministry of Education, Culture, Sports, Science, and Technology of 
Japan. The protocols for animal experiments were approved by the Institutional Animal 




     Human esRAGE protein purified from conditioned media of COS7 cells, which 
had been stably transformed with esRAGE cDNA-expression vector [25], or A1-42 
peptide was immobilized onto BIAcore CM5 research grade sensor chips by the amine 
coupling method in accordance with the supplier’s recommendations. Human esRAGE 
and A1-42 peptide bindings to the immobilized A1-42 peptide and esRAGE protein, 
respectively, were examined with BIAcore 2000 system as described previously [6]; the 
flow buffer used contained 10 mM HEPES (pH 7.4), 0.15 M NaCl, 3 mM Na-EDTA, 
and 0.005% (v/v) surfactant P-20. Association and dissociation were measured at 25C 
at a flow rate of 20 L/min. The sensor chips were regenerated by washing with 10 mM 
NaOH and 0.5% (w/v) SDS. Kinetic parameter was obtained by fitting the sensorgrams 
to a 1:1 (Langmuir) binding model using the BIAevaluation 3.1 software. 
 
Solid-phase reconstitution of a receptor-ligand binding and competition assay 
 
     One hundred g of FAM-labeled A1-42 peptide were dissolved in 50 L of 1% 
NH4OH, dispensed into aliquots and stocked frozen at -20C. The stocked A1-42 
solution was diluted with phosphate-buffered saline (PBS) and used for assay. Each well 
of a 96-well ELISA plate (437915, Nalgene Nunc) was coated with 50 ng of purified 
human esRAGE proteins in 100 L of PBS, and received 200 L of 1 ng/L 
FAM-labeled A1-42 peptide together with varying concentrations of the liquid-phase 
competitor esRAGE proteins. After incubation for 1 hr at 25C, wells were washed 
three times with PBS and underwent the measurement of fluorescence at 
exitation/emission = 485/538 nm using a Fluoroskan Ascent FL (Labotal Scientific 
Equipment Ltd., Abn Gosh, Israel). The ligand binding and competition assay system 
has been successfully applied to other RAGE ligands, including AGE themselves [33]. 
 
Western blot analysis 
 
     Extraction of RAGE proteins from brain in esRAGE Tg, RAGE-null, and WT 
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mice were performed as previously described [34]. One l each of sera from esRAGE 
Tg, RAGE-null, and WT mice or 10 l each of affinity-purified brain extracts from 
esRAGE Tg, RAGE-null, and WT mice were loaded. Proteins were separated by 
SDS-PAGE (12.5%) and electroblotted onto PVDF membranes (Millipore). The 
membranes were blocked with 5% (w/v) non-fat dried milk in PBS and 0.1% (v/v) 
Tween 20, and then incubated with 0.5 g/mL of rabbit anti-human esRAGE-specific 
polyclonal antibody [25] or 1,000-fold diluted goat pan-RAGE antibody (Millipore). 
Anti-Rabbit IRDye 680 and 800 were diluted 10,000-fold and used as the secondary 
antibody. The antigen-antibody complex was visualized using the Odyssey Infrared 
Imaging systems (LI-COR Biotechnology, Linclon, Nebraska, USA). Quantification of 
the intensity of immunoreacted bands was performed with the public domain Image J 




     ELISA kit (B-Bridge International, Inc) was employed to determine serum levels 
of human esRAGE in esRAGE Tg, RAGE-null and WT mice as described previously 
[35]. The ELISA system is not interfered by an addition of ligands. 
 
Radioiodination of A1-42 
 
     Human A1-42 peptides were labeled with 
125
I by the method of chloramine-T as 
described previously [36-38]. Labeling and HPLC purification were carried out at 
Advanced Science Research Center, Kanazawa University. In brief, a solution 
containing human A1-42 (10 g/10 L) and [
125
I]sodium iodide (0.5 mCi/5 L: 0.343 
mCi/8 L) were mixed in 85 L of 0.2 M PBS (pH7.4) on ice. Chloramine-T (10 L, 
3.8 mM) was added to the solution, followed by agitation every 1 min. After 5 min, the 
reaction was terminated by adding Na2S2O5 to a final concentration of 2.5 mM. 
     The reaction mixture (total: 165 L) was applied onto a Zorbax 300 Extend-C18 
(4.6 mm inner diameter x150 mm length) column equilibrated with TBS (pH 7.4) at a 1 
ml/min flow rate at 45°C, and separated with the 
125
I radioactivity and the absorbance at 
220 nm being constantly monitored. The eluates were fractionated into glass tubes (2~4 
mL/tube). Fractions containing labeled A1-42 were collected and further separated in 
the same column but using a 20-60% linear gradient of acetonitrile in 0.1% TFA and a 
flow rate of 1 ml/min. After the chromatography, the solvent in the glass tube was 





was evaluated by paper chromatography. The ratio of the 
radioactivity incorporated into amyloid peptides/the radioactivity loaded on the paper 
chromatography was 2,697.90 x 10
3
 cpm/2,733.99 x 10
3
 cpm = 98.7%. When the ratio 
was greater than 95%, the radiolabeled material was considered pure enough to be used 
for biological analyses; the purified peptides were initially dissolved in DMSO, diluted 
to a concentration of 1 mg/mL in TBS, and analyzed for degree of oligomerization by 
SDS-PAGE. The final radioactivity associated with 125I-labeled A1-42 was estimated to 




     Three groups of C57Bl/6J mice (n=6) were anesthetized with ether and received 
an intravenous bolus injection of 2 Ci of 125I-labeled A1-42 in 0.2 mL of 0.1% BSA 
solution (91 nM as A1-42 concentration). After injection, the animals were euthanized at 
different time point intervals (5, 15, 30, 60, and 120 min). Immediately after blood 
samples were drawn and collected, the blood was washed out of the vascular system by 
infusing 30 mL of 0.1 M PBS (room temperature) at ~6 mL/min through a needle 
inserted into the left ventricle. Blood, brain, lung, liver, kidney, urine, and gallbladder 
were then collected, and weighed at each time point. The radioactivities were measured 
with a -counter (Aloka, ARC-1000, Tokyo), and total cpm were recorded. The resultant 
cpm was normalized to be cpm per gram of wet tissue and is expressed as % dose/g 
tissue. 
 
In vivo autoradiography 
 
     A hundred Ci of 125I-labelled A1-42 tracer (4.6 M as A1-42 concentration) was 
injected into the tail vein. At 30 min after the injection, animals were euthanized and 
blood vessels were immediately perfused. Then, the brain was quickly removed, fixed 
using Tissue-Tek (Sakura Finetek Japan Co., Ltd., Tokyo, Japan) and kept frozen in 
powdered dry ice. Serial coronal sections containing the hippocampus or cerebellum 
were exposed to tritium-imaging plate for 1 week. To quantitatively evaluate the 
autoradiograms, photo-stimulated luminescence (PSL) values were assessed using the 
Bio-Imaging Analyzer System (Fuji Film, Hamamatsu, Japan). Regions of interest 
(ROIs) on the slices included the cerebral cortex, hippocampus, striatum, thalamus, and 
cerebellum. The signal intensities in these regions are expressed as 






     Statistical analysis was performed using ANOVA with StatView software. p<0.05 






Physical binding of A1-42 to esRAGE 
 
     We first examined direct physical binding of human A1-42 to human esRAGE by 
SPR. Purified esRAGE protein bound in a concentration-dependent manner to human 
A1-42 immobilized onto a BIAcore sensor chip (Fig. 1A). The association rate constant 
(ka), dissociation rate constant (kd) and the equilibrium dissociation constant (Kd) of 









44.9 nM, respectively; these are consistent with the previous report [8]. We also found 
A1-42 binding to esRAGE, which was already immobilized onto the sensor chip (Fig. 
1B and C). With this condition, preincubation of either VN1 
(KGAPKKPPQRLEWKLN) or VN2 (WKLNTGRTEAWKVLSPQG) peptide [6] with 
A1-42 led to a dose-dependent reduction in their association (Fig. 1B and C). These 
findings suggest that potential A1-42-binding sites reside in the immunoglobulin V type 
region of esRAGE. Association between A1-40 and the esRAGE was also found and 
both VN1 and VN2 peptides competed their bindings (data not shown). Because A1-42 
has been regarded as the major cause of neurotoxicity at an early stage of AD [15], we 
focused on A1-42 in the subsequent experiments.  
     We next conducted a solid-phase reconstitution of a receptor-ligand binding and 
the competition assay to see whether the binding of A1-42 to RAGE was inhibited by 
esRAGE. The binding of FAM-labeled A1-42 to RAGE was decreased by an addition of 
esRAGE protein in a dose-dependent manner (Fig. 1D). The binding between two was 
almost completely inhibited by more than 100 g/mL of esRAGE in this assay 
condition. 
 
Creation of transgenic mice with high level of human esRAGE in circulation 
 
     We attempted to create an animal model, in which high serum concentration of 
human esRAGE protein is achieved, in order to test the protective potential of this 
variant against AD. For this, we employed the cDNA coding for human esRAGE and 
the murine albumin enhancer/promoter, which was expected to drive an abundant 
production of esRAGE proteins and to liberate them into circulation. Fig. 2A shows a 
schematic representation of the transgene construct. Heterogenous esRAGE Tg mice 
develop normally and are fertile; body weight of the esRAGE Tg was not different from 
that of WT for the observation period of experimentation as was the case for RAGE-null 
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mice (data not shown). Serum from esRAGE Tg clearly gave, but WT or RAGE-null 
mice-derived serum did not, the band immunoreacted with anti-human esRAGE protein 
antibody at 50 kDa, to which human esRAGE proteins migrated (Fig. 2B). When sera 
were assayed with the human esRAGE ELISA system, the mean esRAGE concentration 
was estimated to be 2.39 ± 0.19 g/mL in esRAGE Tg (n= 67) (Fig. 2C). This value was 
more than 4 orders of magnitude higher than the mean in normal human subjects (0.13 ± 
0.06 ng/mL) [35]. Human esRAGE protein was not detected either in WT or RAGE-null 
mice (Fig. 2C). Next we determined the levels of endogenous membrane-bound RAGE 
protein and transgene-derived human esRAGE in brain from WT, RAGE-null and 
esRAGE Tg mice using pan-RAGE antibody with which both membrane-bound RAGE 
and esRAGE of either human or mouse origin can be simultaneously evaluated. As 
shown in Fig. 2D, the membrane-bound RAGE was expressed to a similar extent in 
brain of WT and esRAGE Tg mice. On the other hand, human esRAGE was detected 
only in esRAGE Tg mice. RAGE immunoreactivity was not detected in RAGE-null 
mice. The results thus indicate that the murine albumin promoter-human esRAGE 
transgene did direct the synthesis of large amounts of circulating esRAGE. 
 
Characterization of radiolabeled A1-42 
 
Fig. 3A shows the elution profile of 
125
I-labeled A1-42 in reverse-phase HPLC. 
When eluted with TBS being monitored by absorbance at 220 nm and by -ray counting, 
the peak was marked at 12-13 min of retention time. The fractions around the peak were 
collected and subjected to another reverse-phase HPLC with a 20-60% linear gradient of 
acetonitrile. The most 
125
I-labeled A1-42 was recovered at 36-40% acetonitrile with a 
retention time at 13 min (Fig. 3B). The recovered fractions were then analyzed by 
SDS-PAGE and autoradiography. Before labeling, solubilized A1-42 gave a single band 
at less than 7 kDa in SDS-PAGE, the position to which A1-42 monomers migrated (Fig. 
3C). On the same gel, the 
125
I-labeled A1-42 was run in parallel and autoradiographed. 
A single band was marked at the same position as the CBB-stained cold peptides, 
indicating that the most 
125
I-labeled A1-42 peptides remained in the monomeric but not 
the oligomeric form in this condition. 
 




     Since RAGE is considered to regulate A1-42 transport and equilibrium between 
brain and circulation [22,23], we then administered radiolabeled A1-42 and compared 
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its biodistribution among WT, esRAGE Tg and RAGE-null mice. After intravenous 
bolus injection of 
125
I-labeled A1-42, blood, brain, lungs, liver, gallbladder, kidneys, and 
urine samples were collected at various time points and -ray-counted. The most 
striking difference was observed in the brain. The brain uptake of radiolabeled A1-42 
peaked at 30 min in WT mice (0.3% of injected 
125
I-labeled A1-42), but this was blunted 
both in esRAGE Tg and RAGE-null mice (Fig. 4). The differences between WT and 
esRAGE Tg mice and between WT and RAGE-null mice were statistically significant 
(p<0.0001). The brain uptake at 30 min was not significantly different between esRAGE 
Tg and RAGE-null mice. The uptake by the lung was also less both in esRAGE Tg and 
RAGE-null mice at various time points than in WT controls (Fig. 4). Blood levels of 
125
I-labeled A1-42 were essentially unchanged during the observation period by 120 min 
and not significantly different among WT, esRAGE Tg, and RAGE-null mice. We also 
examined the distribution to metabolic organs, that is, the liver and the kidney, and 
excretion from them (gallbladder and urine). Injected 
125
I-labeled A1-42 seemed to be 
excreted into bile and urine in a time-dependent manner, but we could not detect any 
significant differences in the radioactivities among the three types of animals at every 
time point tested. However, the early liver uptake of 
125
I-labeled A1-42 (15% of injected 
125
I-labeled A1-42 in WT mice) was significantly decreased only in RAGE-null mice at 
5 min and was significantly increased in esRAGE Tg mice at 15 min after the injection 
(Fig. 4). In the kidney, 38% of injected 
125
I-labeled A1-42 was detected in WT mice at 5 
min, and lower radioactivities were noted both in RAGE-null and esRAGE Tg mice at 
15 and 30 min, respectively (Fig. 4). 
 
Radiolabeled A1-42 distribution in various brain regions 
 
     We then conducted autoradiographic analysis of the brain to compare regional 
distribution of radiolabeled A1-42 among WT, esRAGE Tg, and RAGE-null mice. The 
brain was removed 30 min after intravenous injection of 
125
I-labeled A1-42, the time 
point when the significant reduction in the brain uptake of 
125
I-labeled A1-42 was 
observed in esRAGE Tg and RAGE-null mice. The radioactivity was highest at cerebral 
ventricles in WT mouse brain (Fig 5). The signals on cerebral ventricle were 
significantly decreased in RAGE-null and esRAGE Tg mice compared with those of 
WT controls. The signals on hippocampal region of RAGE-null and esRAGE Tg mice 
were weaker than those of WT mice. Fig. 5B shows photo-stimulated luminescence 
(PSL) values at various brain regions among the three types of animals. Because the 
values of the cerebellum were consistently similar among the three groups, the values of 
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the other brain regions were related to those of the cerebellum of the respective animal 
group. Approximately 50% less PSL was recorded in lateral, third, and fourth ventricles 
of RAGE-null and esRAGE Tg mice than in the ventricles of WT mice. Approximately 
30% less PSL was recorded in cerebral cortex, hippocampus, striatum, and thalamus of 
RAGE-null and esRAGE Tg mice than in the respective regions of WT mice. The 
signals on putamen and CA1 and CA3 regions of hippocampus were also statistically 





     The present study has confirmed that human A1-42 can engage the multi-ligand 
receptor RAGE and esRAGE with high affinity (Kd at 44.9 nM). This was demonstrated 
by direct physical association of A1-42 and esRAGE (Fig. 1A, B, and C) and by the 
peptide competitive inhibition (Fig.1B and C), and by solid-phase reconstitution of a 
receptor-ligand binding and the competition assay (Fig.1D). The results are consistent 
with the previous reports [6, 39]. Human A1-42 binding sites of RAGE were found to 
be VN1 (KGAPKKPPQRLEWKLN) and VN2 (WKLNTGRTEAWKVLSPQG) regions 
within the immunoglobulin V type domain of RAGE. The amino acid sequences of VN1 
and VN2 are well conserved between human and mouse; 93.75% sequence identity in 
VN1 and 100% in VN2. In disagreement with this case, we recently reported that LPS 
binding site of RAGE was only VN1 region, not VN2 [6]. With regard to 
esRAGE-binding site in A1-40/1-42, Chaney et al. suggested three negative charged 
residues (3, 7 and 11 of A1-40/1-42 sequence) of A1-40/1-42 as the most important for 
binding of A1-40/1-42 to RAGE by atomic force microscopy and molecular modeling 
[40]. Gospodarska et al. recently reported 17-23 (LVFFAED) residues on A1-40/1-42, a 
highly hydrophobic stretch flanked by negatively charged residues D22E23, were the 
major binding site to RAGE using intrinsic RAGE tryptophan fluorescence and mass 
spectrometry of non-covalent protein-ligand complexes [39]. 
     The previous studies by Mackic et al. [20] and by Deane et al. [23] showed that 
the transport of circulating A1-42 into the brain is dependent on RAGE expressed at 
BBB. Accordingly we established for the first time a transgenic mouse line that could 
abundantly produce circulating esRAGE, which would capture A1-42 and prevent the 
amyloid accumulation in the brain. The murine albumin enhancer/promoter employed in 
the construction of the transgene efficiently directed the synthesis of large amounts of 
human esRAGE in serum (Fig. 2). Total soluble forms of mouse RAGE protein were 
under the detectable level in the circulation of WT control mice (data not shown), 
although we reported the expression of mouse esRAGE mRNA and protein in various 
tissues with high sensitivity techniques [41]. This suggests mouse has more 
predominant membrane-bound RAGE (signaling RAGE) and less soluble form of 
RAGE. Accordingly, we accounted WT mice to be membrane-bound RAGE expressors 
(RAGE >> sRAGE/esRAGE) and the esRAGE Tg mice to be esRAGE >> RAGE 
models. This was supported by immunoblot analysis of brain extracts from WT, 
RAGE-null and esRAGE Tg mice (Fig. 2D); quantitation of band intensities with Image 




     The resultant esRAGE Tg showed a significant reduction in brain uptake of 
radiolabeled A1-42 at 30 min, when the transition of A1-42 from circulation to the brain 
parenchyma peaked in WT mice, as did RAGE-null mice (Fig. 4). The results were 
comparable with a previous report that recombinant soluble RAGE as well as 
anti-RAGE neutralizing antibody blocked 
125
I-A brain capillary uptake and transport 
across BBB [23]. Since esRAGE and sRAGE have the same ligand binding domains, 
this study confirmed the earlier findings showing that sRAGE reduced brain A levels 
[23]. Maximum reduction of cerebral blood flow as well as RAGE-dependent BBB 
transport of A was observed at 30 min after intravenous injection of A1-40 [23]. This 
coincides with the peak levels of A1-42 in brain in the current paper, suggesting that a 
similar hemodynamic mechanism works in the brain receiving either A1-40 or A1-42. In 
the present study, the distribution of radiolabeled A1-42 into various brain regions was 
also investigated. This revealed significant reduction of A1-42 uptake in regions, 
including ventricles, cerebral cortex, hippocampus, striatum, thalamus, and putamen, in 
RAGE-null and esRAGE Tg mice compared with those in WT controls (Fig. 5). Among 
those regions, ventricles exhibited the highest accumulation of 
125
I-A1-42 in WT mice 
and the most decrease in esRAGE Tg and RAGE-null animals (Fig. 5A and B). This 
suggests that there may be abundant or high-affinity RAGE-dependent binding sites for 
A1-42 in the ventricle and choroid plexus. The intense signal on ventricles might partly 
reflect transition of injected 
125
I-A1-42 from bloodstream to cerebrospinal fluid. 
Considerable uptake rates and relative PSL/mm
2
 were noted in the brain and its regions 
in RAGE-null as well as esRAGE Tg mice (Figs. 4 and 5). 
     RAGE-null mice have neither membrane-bound nor esRAGE in the brain, 
periphery, and endothelial surface to transport A at BBB, whereas esRAGE mice have 
excessive esRAGE in the circulation but perhaps normal levels of membrane-bound 
RAGE at BBB to bind A and transport A. One might expect to see a difference 
between esRAGE Tg and RAGE-null mice in the data shown in Figs. 4 and 5. However, 
there seems to be no differences between esRAGE Tg and RAGE-null mice in terms of 
A1-42 amount detected in the brain. This may be ascribed to the higher concentration 
(~g/mL) of human esRAGE in circulation far surpassing the physiologic level of 
mouse RAGE expressed on the surface of endothelial cells in esRAGE Tg mice. In 
addition, the formation of esRAGE-A complexes in circulation and the prevention of 
membrane-bound RAGE-A interaction at BBB would allow the efflux mechanism to 
prevail [23], thereby promoting A clearance from brain in esRAGE Tg mice. 
Among the organs tested, the lung of esRAGE Tg and RAGE-null mice also 
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showed a significant decrease in 
125
I-labeled A1-42 uptake (Fig. 4). The lung is known 
to abundantly express RAGE [41] and may have been endowed with an enriched 
RAGE-mediated mechanism for ligand uptake, as is the case for the BBB. On the other 
hand, 
125
I-A1-42 levels were the same and unchanged in blood during the 120 min in the 
WT, RAGE-null and esRAGE Tg mice (Fig. 4). This may be due to sLRP binding of A 
in plasma [42]. 
     The present study revealed that uptake of radiolabeled A1-42 to CA1 and CA3 
hippocampal regions was decreased by high levels of esRAGE in circulation or by 
RAGE deficiency (Fig. 5B). The pyramidal cells in the CA1 region are reported to be 
vulnerable to degeneration, and this has been related to impaired cognitive function in 
AD [43]. Our previous study revealed that esRAGE immunoreactivity was decreased in 
the same regions of hippocampus in AD brains as for non-AD brains [31]. We speculate 
that, in addition to low expression of esRAGE in the hippocampus, low serum esRAGE 
may become a risk for AD. In effect, Emanuele et al. reported lower plasma soluble 
RAGE levels in AD compared with those in non-AD patients or controls [44]. 
     A and RAGE constitute a vicious cycle of the progression in AD. Ligand 
engagement of RAGE activates the RAGE gene itself via activation of NF-κB, thus 
forming a positive loop of regulation [45,46]. A has been shown to belong to the group 
of ligands that are able to upregulate RAGE expression [47-50]. Moreover, A can 
induce another cascade of post-RAGE signaling; (1) an intracellular calcium 
mobilization activates nuclear factor activated T cells 1 (NFAT1) to upregulate beta-site 
APP-cleaving enzyme (BACE) expression, resulting in -secretase-driven A 
generation [51], (2) cytokine secretion and proinflammatory reactions [52], (3) 
migration of inflammatory cells across BBB [24]. We hypothesize that esRAGE can 
sequester A1-42 for systemic clearance and antagonize A1-42 binding to cell surface 
RAGE, blocking the amplification loop for more RAGE and A1-42 generation on one 
hand, and inhibiting RAGE-mediated transport of A1-42 into the brain on the other, 
thereby preventing amyloid aggregation within the brain and subsequent neuronal death. 
     In conclusion, evidence obtained in the present study suggests a therapeutic 
potential of esRAGE against AD. In addition, circulating soluble RAGE, including 
esRAGE, should be a useful biomarker to predict susceptibility/resistance to AD. 
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Binding of A1-42 to esRAGE and its competition by synthetic peptides of RAGE. 
(A) Surface plasmon resonance (SPR) analysis. esRAGE at varying concentrations was 
perfused onto an A1-42-immobilized BIAcore sensor chip. Thirty seconds after the 
injection, the mobile phase was changed back to the buffer without the analyte. (B, C) 
SPR assays. Thirty g/mL of A1-42 was perfused on the extracellular domain of RAGE 
immobilized on a sensor chip. Thirty seconds after the injection, the mobile phase was 
changed back to the buffer without A1-42. For competition assay, the same 
concentration of A1-42 was preincubated with the indicated concentrations equal to or 
in excess of VN1 or VN2 peptide for 30 min, and the preincubation mixtures were 
injected into the sensor chip on which esRAGE had been immobilized. (D) esRAGE 
immobilized to a 96-well plate was incubated with FAM-labeled A1-42 in the presence 
or absence of indicated concentrations of esRAGE for 1 hr and the intensity of 
fluorescence was detected at exitation/emission = 495/521 nm. 
 
Figure 2  
Generation and characterization of human esRAGE-overexpressing mice. 
(A) Schematic diagram of the transgene carrying human esRAGE cDNA under the 
control of mouse albumin enhancer/promoter. The construct also has human -globin 
intron and SV40 late poly(A) signal (SV40 Poly A). Alb, albumin; Enh, enhancer; Pr, 
promoter. Hga-I, Hga-I site for restriction. (B) Immunoblot analysis of sera from 
wild-type (WT), RAGE-null (KO), and esRAGE Tg (TG) mice with anti-human 
esRAGE antibody. (C) Serum human esRAGE concentrations were determined by 
ELISA in wild-type (WT), RAGE-null (KO) and esRAGE Tg (TG) mice. Data are 
expressed as mean ± SEM. n.d., not detected. (D) Immunoblot analysis of brain tissues 
from wild-type (WT), RAGE-null (KO) and esRAGE Tg (TG) mice with pan-RAGE 




HPLC separation and characterization of radiolabeled A1-42 peptide. 
(A) Chromatography on a Zorbax 300 Extend-C18 column equilibrated and eluted with 
TBS, pH 7.4. The ordinate shows absorbance at 220 nm. Bar, the peak fractions 
collected for further purification. (B) Chromatography on a Zorbax 300 Extend-C18 
column using a 20-60% linear gradient of acetonitrile in 0.1% TFA. The ordinate, 
25 
 
absorbance at 220 nm; bar, the peak fractions collected. (C) SDS-PAGE analysis of 
A1-42 peptides before and after 
125
I-labeling. One g of A1-42 peptides was 
electrophoresed on 5-20% gradient polyacrylamide gel and stained with Coomassie 
brilliant blue (CBB). 5,000 cpm of 
125
I-labeled peptides was run on the same gel and 




Tissue distribution of radiolabeled A1-42 in wild-type (WT), RAGE-null (KO) and 
esRAGE Tg (TG) mice. Animals received intravenous bolus injection of 2 μCi of 
125
I-labeled A1-42 peptides in 0.2 mL of 0.1% BSA solution, and euthanized at 
indicated time points. After blood was drawn, mice were perfused with PBS, and tissues 
were removed, weighed, and processed for γ-counting. Values are expressed as % 
dose/g wet tissue. Data are expressed as mean ± SEM. *, p<0.05; **, p<0.02; 
#
, 
p<0.0001 compared with the value of WT control at each time point. Values for blood 






I-labeled A1-42 within the brains of wild-type (WT), RAGE-null 
(KO) and esRAGE Tg (TG) mice. (A) Typical autoradiograms of horizontal sections. 
LV, lateral ventricle; HIP, hippocampus. (B) Comparison of radiolabeled A1-42 
distributions in various brain regions. Data are expressed as mean ± SEM (n=3) of 
relative photo-stimulated luminescence (PSL)/mm
2
. Values are related to those of the 
cerebellum of each animal group; 1.0 in WT was equivalent to 51.7 PSL/mm
2
; 1.0 in 
RAGE-null mice was to 52.3 PSL/mm
2
; 1.0 in esRAGE Tg to 54.7 PSL/mm
2
. Lat. Vent., 
lateral ventricle: 3rd Vent., third ventricle; 4th Vent., fourth ventricle; CTX, frontal 
cortex; HIP, hippocampus; STR, striatum; THA, thalamus; CA1, CA1 region of HIP; 
CA2, CA2 region of HIP; CA3, CA3 region of HIP; CA4, CA4 region of HIP; DG, 
dentate gyrus. *, p < 0.03; **, p < 0.005; 
#
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